Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The firm develops drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano in 2007 and is headquartered in Purchase, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

- Features Alzheimer's Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. -

Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer's Disease

PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company's management team will participate in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase and BIO Partnering @ JPM. All events will be held in-person and are scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2023.

Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"

SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) will be communicated in an oral presentation at the 2022 Dry AMD Therapeutic Development Summit. Age-related macular degeneration is the leading cause of irreversible central vision loss in the world, with dry AMD affecting an estimated 10 million people in the U.S., 1.5 million of whom have advanced disease or GA.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Fintel reports that Hirschman Orin has filed a 13G form with the SEC disclosing ownership of 2,037,853 shares of Cognition Therapeutics Inc (CGTX).

Orin Hirschman Discloses Large Position in CGTX / Cognition Therapeutics

PURCHASE, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has introduced a new podcast/webinar series named “Conversations,” that will feature virtual fireside chats with neuroscience experts to discuss advances in the research and treatment of Alzheimer's disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.

Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series

PURCHASE, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $1.20 per share. The gross proceeds to Cognition, before deducting underwriting discounts and commissions and estimated offering related expenses, were approximately $6.0 million. In addition, Cognition has granted the underwriters a 30-day option to purchase an additional 750,000 shares of its common stock.

Cognition Therapeutics Announces Closing of Public Offering

- SHINE Alzheimer's Trial Expands to European Sites - - SEQUEL Alzheimer's Trial Awarded Additional NIA Grant to Complete - - Over 50% of SHIMMER Dementia with Lewy Bodies Study Sites Active -

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved Treatments Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved Treatments

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®.

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

PURCHASE, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, announced today that the Company's president and CEO, Lisa Ricciardi will participate in a panel discussion and host one-on-one meetings at the Cantor Fitzgerald Neurology & Psychiatry Conference taking place in San Francisco from October 6-7, 2022.

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today announced that members of management will be participating in two investment conferences in September 2022.

Cognition Therapeutics Announces Participation in September Investment Conferences

Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer's Disease Positive Preliminary Data for Dry AMD Program Presented at ARVO 2022 Proteomics Data from SPARC read out at AAIC

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Presented at Alzheimer's Association International Conference August 4, 2022 Presented at Alzheimer's Association International Conference August 4, 2022

Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer's Disease Processes

- Analyses Demonstrate CT1812 Impact on Alzheimer's Disease Processes -

Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer's Disease

- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association -

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi, Cognition's president and CEO will be presenting an update on the company's progress developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. A live and archived webcast can be accessed here as well as on the company's Events & Presentations webpage.

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

Taking place on June 9 at 10:00 a.m. ET Taking place on June 9 at 10:00 a.m. ET

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation

PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that Lisa Ricciardi, the Company's president and CEO and Mary Hamby, Ph.D., vice president of research, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the release, the report date should be Wednesday, May 11, 2022, not Tuesday as previously stated. The corrected release follows:

CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that it will report financial results for the first quarter ended March 31, 2022 and provide a business update before the financial markets open on Tuesday, May 11, 2022.

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) summarizing preclinical results showing that sigma-2 (σ-2) receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration (dry AMD). Cognition plans to initiate a Phase 2 clinical study for CT1812, the company's lead σ-2 receptor modulator, in patients with dry AMD.

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team will participate in a virtual fireside chat at the B. Riley Securities' Neuro & Ophthalmology Conference taking place from April 27-28, 2022.

News for Cognition Therapeutics Stock (CGTX)